Abstract | BACKGROUND: PATIENTS AND METHODS: Patients with colorectal cancer (CRC) (n=63) were enrolled into two phase I/II dose escalation trials of PTK/ZK in 28-day cycles until discontinuation. Patients with stable disease for > or =2 months were categorized as 'non-progressors'. Plasma markers of angiogenesis, VEGF-A and basic fibroblast growth factor (bFGF), and the serum markers of activated endothelial cells, sTIE-2 and sE- Selectin, were assessed at baseline, and pre-dose on days 1, 8, 15, 22 and 28 of every cycle, with additional assessments 10 h post-dose on days 1 and 15. The percentage change from baseline was subsequently correlated with AUC and C(max) of PTK/ZK on day 1, cycle 1 and clinical outcome. RESULTS: A dose-dependent increase in plasma VEGF-A and bFGF was observed in the first cycle of PTK/ZK treatment. The correlation of change in plasma VEGF-A with AUC and C(max) was characterized by an E(max) model, suggesting that a change of > or =150% from baseline VEGF-A correlated with non-progressive disease. Change from baseline plasma VEGF-A within the first cycle of treatment was significantly correlated with clinical outcome by logistic regression analysis (P=0.027). CONCLUSIONS: In patients with CRC treated with PTK/ZK, changes in plasma VEGF-A and bFGF demonstrate biological activity of PTK/ZK, may help to establish optimal dose and correlate with outcome.
|
Authors | J Drevs, U Zirrgiebel, C I M Schmidt-Gersbach, K Mross, M Medinger, L Lee, J Pinheiro, J Wood, A L Thomas, C Unger, A Henry, W P Steward, D Laurent, D Lebwohl, M Dugan, D Marmé |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 16
Issue 4
Pg. 558-65
(Apr 2005)
ISSN: 0923-7534 [Print] England |
PMID | 15705616
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers
- Phthalazines
- Protein Kinase Inhibitors
- Pyridines
- vatalanib
- Receptors, Vascular Endothelial Growth Factor
|
Topics |
- Aged
- Biomarkers
(blood)
- Clinical Trials, Phase II as Topic
(methods)
- Colorectal Neoplasms
(blood, drug therapy, enzymology)
- Dose-Response Relationship, Drug
- Female
- Humans
- Male
- Middle Aged
- Phthalazines
(pharmacology, therapeutic use)
- Protein Kinase Inhibitors
(pharmacology, therapeutic use)
- Pyridines
(pharmacology, therapeutic use)
- Receptors, Vascular Endothelial Growth Factor
(antagonists & inhibitors, blood)
|